Accredited Educational Activities

CLICK ON STATES TO SEE LIVE ACTIVITIES

ONLINE ACTIVITIES

Jun
17
Wed
Seeing New Possibilities in Retinal Disease: Anti-VEGF Therapies and Beyond
Jun 17 2020 @ 8:00 am – Oct 1 2022 @ 9:00 am

Seeing New Possibilities in Retinal Disease: Anti-VEGF Therapies and Beyond

View Activity

FACULTY

Dilsher Dhoot, MD
California Retina Consultants
Adjunct Clinical Assistant Professor of Ophthalmology
Keck School of Medicine (USC)
Santa Barbara, CA

Steven Ferrucci, OD, FAAO
Chief of Optometry, Sepulveda VA Medical Center
Los Angeles, CA
Professor, Southern California College of Optometry at Marshall B. Ketchum University
Fullerton, CA

PROGRAM OVERVIEW

This online activity targets healthcare gaps related to the recognition, prevention, and management of diabetic retinopathy (DR). An expert panel discussion will guide you in identifying candidates for anti-VEGF therapy, review clinical trial data on the use of these agents, and provide evidence-based strategies to individualize the management of DR and overcome treatment barriers.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with diabetic retinopathy.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Integrate evidence-based prevention, diagnostic, and treatment strategies for retinal disease into clinical workflow
  • Identify patients with diabetic retinopathy (DR), who would benefit from anti-vascular endothelial growth factor therapy (anti-VEGF) therapy
  • Explain the rationale for intervening early in the disease process when treating patients with DR

ACCREDITATION STATEMENT: Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT: Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION: Purpose: This program would be beneficial for nurses involved in the care of patients with diabetic retinopathy. CNE Credits: 1.0 ANCC Contact Hour.

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Steven Ferrucci, OD, FAAO discloses the following financial interests or relationships:

  • Consultant: Centervue, Science Based Health, Visible Genomics
  • Speakers’ Bureau: Genentech, MacuLogix, Regeneron, Notal Vision

Dilsher Dhoot, MD discloses the following financial interests or relationships:

  • Consultant: Allergan, Alimera, Bayer, Eyepoint, Genentech, Regenex, Regeneron, Novartis
  • Speakers’ Bureau: Alimera, Eyepoint, Genentech, Regeneron, Novartis

CME Content Review

The content of this activity was independently peer reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN

Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to d
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to
  • Nicole Longo, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Diana Tommasi, Medical Director of Med Learning Group, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to
  • Amanda Jenkins, Program Coordinator of Med Learning Group, has nothing to disclose.
  • Daniel Dasilva, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

RELEASE DATE: October 01, 2021

EXPIRATION DATE: October 01, 2022

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

View Activity

Jun
18
Thu
Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease: Diabetic Retinopathy (Optometry)
Jun 18 2020 @ 8:06 am – Sep 13 2022 @ 9:06 am

Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease: Diabetic Retinopathy (Optometry)

View Activity

FACULTY

A. Paul Chous, MA, OD, FAAO
Specializing in Diabetes Eye Care & Education
Tacoma, WA
Adjunct Professor
Western University of Health Sciences
Pomona, CA

PROGRAM OVERVIEW

This online activity targets healthcare gaps related to evidence-based recognition and prevention as well as timely treatment and management of diabetic retinopathy (DR), impacting visual outcomes through guidelines and best practices, clinical trial data and strategies to facilitate earlier initiation of therapy.

  • By addressing these gaps, you can assess whether your approach to DR management through utilization of current treatment guidelines, individualization of treatment approach and strategies for overcoming treatment barriers – could be modified to help close these gaps.
  • Expert discussion will guide you in analyzing and identifying appropriate candidates for anti-VEGF therapy, utilizing guidelines and clinical trial data on efficacy and safety to affect patient outcomes.
  • You will also be immersed in dynamic animations utilizing a virtual reality platform to memorably highlight key points related to nonproliferative and proliferative retinopathy and the mainstays of treatment for retinopathy.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with diabetic retinopathy.


LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Incorporate consistent use of evidence-based screening and prevention strategies for patients at risk of DR
  • Apply clinical trial data and guidelines to the selection of therapies for the treatment of patients with DR
  • Identify barriers to early intervention and communicate to patients the importance for early initiation of therapy in DR

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in online activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with DR.
CNE Credits: 1.0 ANCC Contact Hour.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/(CCM) is accredited as a provider of nursing continuing professional education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Paul Chous, MA, OD, FAAO is a consultant for EyePromise, Regeneron Pharmaceuticals, and VSP Vision Care. Dr. Chous is on the speakers’ bureau for Regeneron and VSP and has received fees for non-continuing medical education/continuing education (CME/CE) serves from Regeneron and VSP.

CME Content Review

The content of this activity was independently peer reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse. The reviewer has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to d
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to
  • Amanda Jenkins, Program Coordinator of Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

RELEASE DATE: September 17, 2021

EXPIRATION DATE: September 17, 2022

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jun
20
Sat
Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease: Diabetic Retinopathy (Retina/Ophthalmology)
Jun 20 2020 @ 8:06 am – Sep 15 2022 @ 9:06 am

Seeing Past the Treatment Horizon: Anti-VEGF Therapies and Beyond in Retinal Disease: Diabetic Retinopathy (Retina/Ophthalmology)

View Activity

FACULTY

Charles C. Wykoff, MD, PhD
Director of Research, Retina Consultants of Texas
Chairman of Research and Clinical Trials Subcommittee, Retinal Consultants of America
Deputy Chair of Ophthalmology, Blanton Eye Institute & Houston Methodist Hospital
Houston, TX

PROGRAM OVERVIEW

This online activity targets healthcare gaps related to evidence-based recognition and prevention as well as timely treatment and management of diabetic retinopathy (DR), impacting visual outcomes through guidelines and best practices, clinical trial data and strategies to facilitate earlier initiation of therapy.

  • By addressing these gaps, you can assess whether your approach to DR management through utilization of current treatment guidelines, individualization of treatment approach and strategies for overcoming treatment barriers – could be modified to help close these gaps.
  • Expert discussion will guide you in analyzing and identifying appropriate candidates for anti-VEGF therapy, utilizing guidelines and clinical trial data on efficacy and safety to affect patient outcomes.
  • You will also be immersed in dynamic animations utilizing a virtual reality platform to memorably highlight key points related to nonproliferative and proliferative retinopathy and the mainstays of treatment for retinopathy.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with diabetic retinopathy.


LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Incorporate consistent use of evidence-based screening and prevention strategies for patients at risk of DR
  • Apply clinical trial data and guidelines to the selection of therapies for the treatment of patients with DR
  • Identify barriers to early intervention and communicate to patients the importance for early initiation of therapy in DR

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with DR.
CNE Credits: 1.0 ANCC Contact Hour.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/(CCM) is accredited as a provider of nursing continuing professional education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Charles C. Wykoff, MD, PhD has provided the following disclosures:

  • Consultant: Acucela, Adverum Biotechnologies, Alimera Sciences, Allegro, Allergan, Apellis Pharmaceuticals, Arctic Vision, Bausch + Lomb, Bayer, Chengdu Kanghong Biotech, DORC, EyePoint Pharmaceuticals, Genentech, Gyroscope, Iveric Bio, Kodiak Sciences, Merck, NGM Biopharmaceuticals, Novartis, ONL Therapeutics, Opthea, Oxurion, Palatin, PolyPhotonix, RecensMedical, Regeneron Pharmaceuticals, REGENXBIO, Roche, and Takeda
  • Research support: Adverum, Aerie Pharmaceuticals, Alder Biopharmaceuticals, Apellis, Chengdu Kanghong Biotech, Clearside Biomedical, Gemini Therapeutics, Genentech, Graybug Vision, Ionis Pharmaceuticals, Kodiak Sciences, LMRI, Neurotech Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Opthea, Outlook Therapeutics, RecensMedical, Regeneron, REGENXBIO, Roche, Samsung Bioepis, Santen Pharmaceutical, Senju Pharmaceutical, and Xbrane Biopharma
  • Ownership/Stock: ONL Therapeutics, PolyPhotonix, RecensMedical, Visgenx

CME Content Review

The content of this activity was independently peer reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse. The reviewer has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to d
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to
  • Amanda Jenkins, Program Coordinator of Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Outcomes and Accreditation Coordinator of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

RELEASE DATE: September 17, 2021

EXPIRATION DATE: September 17, 2022

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jun
22
Mon
Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Diabetic Retinopathy – VA Grand Rounds Enduring Activity
Jun 22 2020 @ 8:06 am – Jun 22 2022 @ 9:06 am

Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Diabetic Retinopathy

View Activity

FACULTY

Rishi P. Singh, MD
Staff Surgeon
Cleveland Clinic Cole Eye Institute
Associate Professor Ophthalmology
Case Western Reserve University School of Medicine
Cleveland, OH

PROGRAM OVERVIEW

This online activity targets healthcare gaps correlated with screening, multidisciplinary care and timely intervention in diabetic retinopathy (DR), which can impact vision-related quality of life.

  • By addressing these gaps, you can assess whether your approach to DR management through screening, utilization of clinical trial data to guide appropriate treatment and multidisciplinary coordination for comprehensive DR management – could be modified to help both strategize treatment design and close these gaps.
  • Expert discussion will guide you in identifying appropriate opportunities for early intervention, as well as assessing impact that DR can have on vision-related quality of life.
  • You will also be immersed in dynamic whiteboard animations to memorably highlight key points related to how the inflammatory and vascular endothelial growth factor (VEGF) pathways lead to the development of DR, as well as the fundoscopic retinal changes associated with each retinopathy stage.

TARGET AUDIENCE

This online CME activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists, primary care providers, managed care providers, pharmacists and other healthcare providers who manage patients with diabetic retinopathy.

LEARNING OBJECTIVES

  • Communicate the importance of proper eye care and early intervention in preventing progressive visual changes in patients with or at risk for DR
  • Incorporate collaborative strategies into clinical practice that promote team-based communication, maintain continuity of care, and improve treatment adherence for patients with or who are at risk for DR
  • Identify pathogenic changes in DR that would be best managed with a multidisciplinary approach
  • Evaluate clinical trial data on the efficacy and safety of currently available treatment options for the management of DR

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity. 

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with diabetic retinopathy.

CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Faculty Member Disclosures
Rishi P. Singh, MD Has received consulting fees from Novartis, Genentech, Regeneron, Alcon, Bausch and Lomb, and Gyroscope. Dr. Singh has contracted research with Aerie, Graybug, and Apellis.

 

CME Content Review

The content of this activity was independently peer-reviewed.

The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer-reviewed by a nurse reviewer.

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
  • Marissa Mays-Verman, Program Manager of Med Learning Group, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
  • Brianna Hanson, MPH, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete online pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

 

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

 

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

 

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Jul
23
Thu
Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Diabetic Retinopathy
Jul 23 2020 @ 7:16 am – May 11 2022 @ 8:16 am

Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Diabetic Retinopathy

View Activity

FACULTY

Rishi P. Singh, MD
Staff Surgeon
Cleveland Clinic Cole Eye Institute
Associate Professor Ophthalmology
Case Western Reserve University School of Medicine
Cleveland, OH

PROGRAM OVERVIEW

This online activity targets healthcare gaps correlated with screening, multidisciplinary care and timely intervention in diabetic retinopathy (DR), which can impact vision-related quality of life.

  • By addressing these gaps, you can assess whether your approach to DR management through screening, utilization of clinical trial data to guide appropriate treatment, and multidisciplinary coordination for comprehensive DR management – could be modified to help both strategize treatment design and close these gaps.
  • Expert discussion will guide you in identifying appropriate opportunities for early intervention, as well as assessing the impact that DR can have on vision-related quality of life.
  • You will also be immersed in dynamic whiteboard animations to memorably highlight key points related to how the inflammatory and vascular endothelial growth factor (VEGF) pathways lead to the development of DR, as well as the fundoscopic retinal changes associated with each retinopathy stage.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists, primary care providers, managed care providers, pharmacists and other healthcare providers who manage patients with diabetic retinopathy.


LEARNING OBJECTIVES

  • Communicate the importance of proper eye care and early intervention in preventing progressive visual changes in patients with or at risk for DR
  • Incorporate collaborative strategies into clinical practice that promote team-based communication, maintain continuity of care, and improve treatment adherence for patients with or who are at risk for DR
  • Identify pathogenic changes in DR that would be best managed with a multidisciplinary approach
  • Evaluate clinical trial data on the efficacy and safety of currently available treatment options for the management of DR

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with diabetic retinopathy.
CNE Credits: 1.0 ANCC Contact Hour.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacists and Pharmacy Technicians
Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hour.
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Rishi P. Singh, MD has received consulting fees from Novartis, Genentech, Regeneron, Alcon, Bausch and Lomb, and Gyroscope. Dr. Singh has contracted research with Aerie, Graybug, and Apellis.

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: May 11, 2021

EXPIRATION DATE: May 11, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].


Enduring Learner Notification

Med Learning Group
Seeing Clearer: Optimizing the Use of VEGF Inhibitors in Diabetic Retinopathy – Enduring
Date of CE Release: May 11, 2021
Date of CE Expiration: May 11, 2022
Online

Acknowledgement of Financial Commercial Support
Regeneron

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. You must attend the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacists and Pharmacy Technicians
Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.
UAN(s): JA4008163-9999-21-077-H04-P / JA4008163-9999-21-077-H04-T

NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

Objectives – After Attending This Program You Should Be Able To

  1. Communicate the importance of proper eye care and early intervention in preventing progressive visual changes in patients with or at risk for DR.
  2. Incorporate collaborative strategies into clinical practice that promote team-based communication, maintain continuity of care, and improve treatment adherence for patients with or who are at risk for DR.
  3. Identify pathogenic changes in DR that would be best managed with a multidisciplinary approach.

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5).

All individuals in a position to control the content of CE are listed below:

 

Name Relationship: Commercial Interest
Ana Maria Albino NA
Matthew Frese NA
Christina Gallo NA
Brianna Hanson NA
Nicole Longo NA
Scott McGee-Plys NA
Rishi P. Singh Consultant: Alcon, Bausch and Lomb, Genentech, Gyroscope, Novartis, Regeneron; Contracted Research with Aerie, Apellis, Graybug
Lauren Welch NA

How to Get Your Certificate

  1. Go to http://mlg.cmecertificateonline.com
  2. Click on “Seeing Clearer: Optimizing the Use of VEGF Inhibitors in Diabetic Retinopathy – Enduring” link.
  3. Complete the post-test, click the provided link to go to the online evaluation site.
  4. Evaluate the meeting, click the provided link to open your credit certificate.
  5. Print/save all pages of your certificate for your records.

Questions?
Email [email protected]

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

View Activity

Jul
24
Fri
Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Diabetic Retinopathy Immersive Simulation Experience
Jul 24 2020 @ 1:00 am – Feb 18 2022 @ 2:00 am

Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Diabetic Retinopathy
Immersive Simulation Experience

View Activity

FACULTY


Allen C. Ho, MD, FACS
Attending Surgeon and Director of Retina Research, Wills Eye Hospital
Professor of Ophthalmology, Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA

PROGRAM OVERVIEW

The diabetic retinopathy (DR) Immersive Simulation Experience allows learners to engage in clinical decision-making targeting diagnosis and therapeutic approaches in DR management. By participating in this simulated 3D encounter, you will observe patient-provider interactions and use pertinent information from the patients’ electronic chart to decide the next best course of action at various key points in care. Highlighted areas for this activity include assessment of retinopathy severity, intensification of treatment, as well as the recognition and management of adverse events.


TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with diabetic retinopathy.


LEARNING OBJECTIVES

  • Communicate the importance of proper eye care and early intervention in preventing progressive visual changes in patients with or at risk for DR
  • Incorporate collaborative strategies into clinical practice that promote team-based communication, maintain continuity of care, and improve treatment adherence for patients with or who are at risk for DR
  • Identify pathogenic changes in DR that would be best managed with a multidisciplinary approach
  • Evaluate clinical trial data on the efficacy and safety of currently available treatment options for the management of DR

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with diabetic retinopathy.
CNE Credits: 1.0 ANCC Contact Hour.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Allen Ho discloses the following:

  • He is a consultant/advisor for Adverum Biotechnologies, Aerie Pharmaceuticals, Alcon Laboratories, Aldeyra Therapeutics, Allergan, Apellis Pharmaceuticals, Applied Genetic Technologies Corporation (AGTC), AsclepiX Therapeutics, Beaver-Visitec International, BioTime, Chengdu Kanghong Biotechnology, Genentech, Graybug Vision, Gyroscope Therapeutics, IRIDEX, Iveric/Ophthotech, Johnson & Johnson, Lineage Cell Therapeutics/ BioTime, Notal Vision, ONL Therapeutics, Optovue, PanOptica, Regeneron Pharmaceuticals, and REGENXBIO
  • He has received grants from Aerie, AGTC, Alcon Laboratories, Aldeyra, Allergan, Apellis, BioTime, Chengdu Kanghong Biotechnology, Genentech, Gemini Medical, Graybug Vision, Gyroscope, Iveric/Ophthotech, Johnson & Johnson, Lineage/BioTime, LumiThera, National Eye Institute, Novartis, Optovue, ProQR Therapeutics, Regeneron Pharmaceuticals, REGENXBIO, and Sanofi
  • He has ownership in Covalent Medical, ONL Therapeutics, and PanOptica

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: March 18, 2021

EXPIRATION DATE: March 18, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/.

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jul
25
Sat
Seeing Beyond the Disease: Reducing the Burden of Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy Through Early Intervention
Jul 25 2020 @ 1:00 am – Feb 19 2022 @ 2:00 am

Seeing Beyond the Disease: Reducing the Burden of Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy Through Early Intervention

View Activity

FACULTY

Neil M. Bressler, MD
James P. Gills Professor of Ophthalmology
Professor of Ophthalmology, Johns Hopkins University School of Medicine
Wilmer Eye Institute, Johns Hopkins Medicine
Baltimore, MD

Participation by Dr. Neil Bressler in this activity does not constitute or imply endorsement by the Johns Hopkins University, the
Johns Hopkins Hospital, or the Johns Hopkins Health System nor by JAMA Ophthalmology.

 


PROGRAM OVERVIEW

This online activity targets healthcare gaps correlated with early intervention in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and diabetic retinopathy (DR) without center-involved macular edema, which can have a profound impact on vision-related quality of life.

  • By addressing these gaps, you can assess whether your approach to nAMD, DME and DR management through utilization of clinical trial data, guideline-based treatment approaches and patient-specific factors – could be modified to help both strategize treatment design and close these gaps.
  • Expert discussion will guide you in identifying appropriate opportunities for early intervention, as well as assessing impact that early vs delayed intervention can have on vision-related quality of life.
  • You will also be immersed in dynamic animations utilizing virtual reality and whiteboard platforms to memorably highlight key points related to how visual acuity is affected by intervention at different disease stages or treatment delay, as well as the impact of anti-vascular endothelial growth factor (anti-VEGF) therapy on the pathophysiologic defects associated with nAMD, DME and DR.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists, and managed care professionals who manage patients with nAMD, DME, and DR in the absence of center-involved DME.


LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Evaluate clinical trial evidence on the optimization of monitoring, treatment dosing, and the association of early intervention on visual acuity outcomes in neovascular AMD (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR) in the absence of center-involved DME
  • Assess the impact of treatments for nAMD, DME, and DR in the absence of center-involved DME on patients’ patient-reported vision-related quality of life
  • How to develop treatment plans for the management of nAMD, DME, and DR in the absence of center-involved DME that incorporate evidence from clinical trials, guideline recommendations, and patient-specific factors

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with nAMD, DME, and DR in the absence of center-involved DME.
Credits: 1.0 ANCC Contact Hour.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Neil Bressler, MD receives grants to his institution for his research efforts from Bayer, Biogen, Novartis, Roche/Genentech, and Samsung Bioepis. He also serves as Chair of the National Eye Institute Data and Safety Monitoring Committee for Intramural Trials for the Emmes Company. He is also Editor in Chief of JAMA Ophthalmology.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse.
The reviewer has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Brianna Hanson, Outcomes and Accreditation Coordinator, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the enduring activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].

RELEASE DATE: February 19, 2021

EXPIRATION DATE: February 19, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

A Virtual Reality Learning Experience: Integrating GLP-1 Receptor Agonists into T2DM Practice—Why, When, and How

Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Scroll to Top
Menu

Search

Clinician Scientific & Educational Resources

The RELIEF Clinical Toolkit is an online tool that aims to provide clinicians with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for diabetic retinopathy (DR) in patients with diabetes who have or are at risk for developing DR. Click on one of the options below to learn more about DR.

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Copyright © 2019 | Diabetic Retinopathy | All Rights Reserved | Website by Divigner

Scientific Council

Neil M. Bressler, MD

James P. Gills Professor of Ophthalmology
Professor of Ophthalmology, Johns Hopkins University School of Medicine
Wilmer Eye Institute, Johns Hopkins Medicine
Baltimore, MD

A. Paul Chous, MA, OD, FAAO

Specializing in Diabetes Eye Care & Education, Chous Eye Care Associates
Adjunct Professor of Optometry, Western University of Health Sciences
AOA Representative, National Diabetes Education Program
Tacoma, WA

Steven Ferrucci, OD, FAAO

Chief of Optometry, Sepulveda VA Medical Center
Professor, Southern California College of Optometry at Marshall B. Ketchum University
Sepulveda, CA

Julia A. Haller, MD

Ophthalmologist-in-Chief
Wills Eye Hospital
Philadelphia, PA

Allen C. Ho, MD, FACS

Director, Retina Research
Wills Eye Hospital
Professor and Chair of the Department of Ophthalmology
Thomas Jefferson University Hospitals
Philadelphia, PA

Charles C. Wykoff, MD, PhD

Director of Research, Retina Consultants of Houston
Associate Professor of Clinical Ophthalmology
Blanton Eye Institute & Houston Methodist Hospital
Houston, TX